| 62.37 1.27 (2.08%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 73.2 |
1-year : | 85.5 |
| Resists | First : | 62.67 |
Second : | 73.2 |
| Pivot price | 60.85 |
|||
| Supports | First : | 57.44 |
Second : | 54.2 |
| MAs | MA(5) : | 61.53 |
MA(20) : | 59.84 |
| MA(100) : | 51.5 |
MA(250) : | 49.31 |
|
| MACD | MACD : | 1.6 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 84.6 |
D(3) : | 86.1  |
| RSI | RSI(14): 69.4 |
|||
| 52-week | High : | 62.67 | Low : | 41.88 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BMY ] has closed above the upper band by 2.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 43.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 61.64 - 61.98 | 61.98 - 62.26 |
| Low: | 59.82 - 60.25 | 60.25 - 60.6 |
| Close: | 60.46 - 61.11 | 61.11 - 61.65 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Sat, 28 Feb 2026
Harvest Portfolios Group Inc. Grows Position in Bristol Myers Squibb Company $BMY - MarketBeat
Sat, 28 Feb 2026
Quantbot Technologies LP Buys 354,309 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Sat, 28 Feb 2026
Bristol Myers Squibb Company $BMY Shares Purchased by DNB Asset Management AS - MarketBeat
Fri, 27 Feb 2026
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
Fri, 27 Feb 2026
Bristol Myers Squibb Pipeline Updates And Valuation Picture For Investors - simplywall.st
Fri, 27 Feb 2026
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq? - Barchart.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 2,040 (M) |
| Held by Insiders | 2.03e+009 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 36,580 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 392.1 |
| Profit Margin | 14.6 % |
| Operating Margin | 28.1 % |
| Return on Assets (ttm) | 10.2 % |
| Return on Equity (ttm) | 40.4 % |
| Qtrly Rev. Growth | 1.2 % |
| Gross Profit (p.s.) | 1.2069e+011 |
| Sales Per Share | 1.66172e+011 |
| EBITDA (p.s.) | 6.5931e+010 |
| Qtrly Earnings Growth | 1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 14,160 (M) |
| PE Ratio | 18.04 |
| PEG Ratio | 0 |
| Price to Book value | 0.15 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.99 |
| Dividend | 0 |
| Forward Dividend | 2.989e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|